A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0148-0000-0287 in Healthy Subjects and in Subjects With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2013
At a glance
- Drugs Insulin 287 (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 30 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.